Clever Leaves Holdings (Clever Leaves Holdings) Debt-to-Equity : 0.09 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Clever Leaves Holdings Debt-to-Equity?

Clever Leaves Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.88 Mil. Clever Leaves Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.20 Mil. Clever Leaves Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $24.22 Mil. Clever Leaves Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Clever Leaves Holdings's Debt-to-Equity or its related term are showing as below:

CLVR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.35 Max: 0.74
Current: 0.09

During the past 5 years, the highest Debt-to-Equity Ratio of Clever Leaves Holdings was 0.74. The lowest was 0.09. And the median was 0.35.

CLVR's Debt-to-Equity is ranked better than
74.53% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs CLVR: 0.09

Clever Leaves Holdings Debt-to-Equity Historical Data

The historical data trend for Clever Leaves Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clever Leaves Holdings Debt-to-Equity Chart

Clever Leaves Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.74

0.36

0.35

0.10

0.09

Clever Leaves Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												0.10	0.07	0.07	0.08	0.09

Competitive Comparison of Clever Leaves Holdings's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clever Leaves Holdings's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Clever Leaves Holdings's Debt-to-Equity falls into.

Clever Leaves Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Clever Leaves Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.884	+	1.203)	/	24.217
	=	0.09

Clever Leaves Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.884	+	1.203)	/	24.217
	=	0.09

Clever Leaves Holdings (NAS:CLVR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Clever Leaves Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Clever Leaves Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Clever Leaves Holdings (Clever Leaves Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clever Leaves Holdings Inc (NAS:CLVR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

19-B Parque Industrial Tibitoc, Tocancipá, Cundinamarca, Bodega, Colombia, BC, CAN

Website

https://www.cleverleaves.com

Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments, 1. The Cannabinoid operating segment: is comprised of the Company's cultivation, extraction, and commercialization of cannabinoid products. 2. Non-Cannabinoid operating segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.

Executives

Andres Fajardo	director, officer: President	CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Julian Wilches	officer: Chief Regulatory Officer	CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Hague Henry R Iii	officer: Chief Financial Officer	489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Gary M Julien	director	ONE LANDMARK SQUARE, 22ND FLOOR, STAMFORD CT 06901
William Muecke	director	C/O CLEVER LEAVES HOLDINGS, 6501 CONGRESS AVE, SUITE 240, BOCA RATON FL 33487
David Kastin	officer: General Counsel	C/O VITAMIN SHOPPE, INC., SECAUCUS NJ 07094
Kyle Detwiler	director, officer: Chief Executive Officer	CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
George J Schultze	10 percent owner	C/O SCHULTZE ASSET MANAGEMENT, LLC, 3000 WESTCHESTER AVENUE, PURCHASE NY 10577
Elisabeth H Demarse	director	CREDITCARDS.COM, 13809 RESEARCH BOULEVARD, SUITE 906, AUSTIN TX 78750
Etienne H. Deffarges	director	ACCRETIVE HEALTH, INC., 401 NORTH MICHIGAN AVENUE, SUITE 2700, CHICAGO IL 60611
Schultze Special Purpose Acquisition Sponsor, Llc	10 percent owner	800 WESTCHESTER AVENUE, SUITE 632, RYE BROOK NY 10573
Amit Pandey	officer: Interim CFO	CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017